Syndax Pharmaceuticals

About:

Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.

Website: http://www.syndax.com

Twitter/X: syndax

Top Investors: Hercules Capital, OrbiMed, Fidelity, Cormorant Asset Management, Biotechnology Value Fund

Description:

Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.